Management of Chronic Small Vessel Ischemic Changes and Vascular Calcification

Initial Assessment and Risk Stratification

The European Society of Cardiology recommends performing a thorough cardiovascular risk assessment using a validated risk-estimation system such as SCORE for asymptomatic adults over 40 years without evidence of cardiovascular disease, diabetes, chronic kidney disease, or familial hypercholesterolemia 1
Assessing family history of premature cardiovascular disease is part of cardiovascular risk assessment, as defined by the European Heart Journal 1, 2
The presence of chronic small vessel ischemic changes is a marker of systemic atherosclerosis, which is associated with increased risk of both stroke and coronary events, according to the Journal of the American College of Cardiology 3, 4

For patients with neurological symptoms, the American Heart Association recommends following guidelines for acute stroke care with appropriate neuroimaging 5
Carotid ultrasound is considered to assess the degree of stenosis in the extracranial portions of the carotid arteries, as suggested by the Journal of the American College of Cardiology 3
Advanced vascular imaging, such as CT angiography (CTA) or MR angiography (MRA), is recommended to determine the extent of underlying coronary and cerebrovascular disease, according to the Journal of the American College of Radiology 6

The European Society of Cardiology recommends implementing aggressive risk factor modification targeting hypertension, with control office blood pressure to target values of 120-130 mmHg systolic for the general population and 130-140 mmHg systolic for older patients (>65 years) 2
Hyperlipidemia management involves optimizing LDL-C levels according to risk category, as recommended by the European Heart Journal 1
Diabetes management involves achieving optimal glycemic control with HbA1c targets, according to the European Heart Journal 2
Smoking cessation is recommended, as suggested by the Journal of the American College of Radiology 7
Weight management and lifestyle modification are also recommended, according to the European Heart Journal 1
Antiplatelet therapy (e.g., aspirin) is recommended for secondary prevention, as suggested by the Journal of the American College of Radiology 7
Statins are recommended for lipid management, according to the European Heart Journal 1
Antihypertensive medications, such as ACE inhibitors or ARBs, are recommended, especially in patients with diabetes, as suggested by the European Heart Journal 2

Periodic visits are recommended to reassess risk status, evaluate treatment adherence, and monitor for development of comorbidities, according to the European Heart Journal 1
Risk stratification is recommended using stress imaging or exercise stress ECG for patients with worsening symptoms, as suggested by the European Heart Journal 1

For patients with carotid calcification and concomitant coronary artery disease, myocardial revascularization is considered if angina persists despite optimal medical therapy, according to the European Heart Journal 1
For patients with diabetes and carotid calcification, sodium-glucose co-transporter 2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) are recommended, as suggested by the European Heart Journal 2
Glucagon-like peptide-1 receptor agonists (liraglutide or semaglutide) are also recommended for patients with diabetes and carotid calcification, according to the European Heart Journal 2

Patients with symptomatic cerebral ischemia related to carotid disease should be referred for vascular specialist evaluation, although this recommendation is from Praxis Medical Insights, a similar recommendation is made by the European Heart Journal 1
Evidence of rapidly progressive stenosis that threatens complete occlusion warrants urgent vascular consultation, although this recommendation is from Praxis Medical Insights, a similar recommendation is not found in other sources

The combination of ACE inhibitors and ARBs is not recommended, as suggested by the European Heart Journal 2
In patients with chronic kidney disease, special attention should be paid to potential dose adjustments of renally excreted drugs and minimizing the use of iodinated contrast agents, according to the European Heart Journal 2
For elderly patients, particular attention should be paid to medication side effects, intolerance, and potential overdosing, as recommended by the European Heart Journal 2